Xeljanz (tofacitinib)

Xeljanz and Xeljanz XR are aimed at reducing psoriatic arthritis inflammation.

What is Xeljanz?

What is Xeljanz?

Xeljanz and Xeljanz XR are the brand names for the oral systemic treatment tofacitinib. Different oral systemic treatments work in different ways to reduce symptoms of psoriatic disease. Newer oral systemic treatments, such as Xeljanz, work similarly to biologics by targeting specific parts of the immune system to reduce symptoms and inflammation.

How Does Xeljanz Work?

Xeljanz targets a specific part of the immune system (Janus kinase) to reduce the overactive response associated with psoriatic disease. The oral treatment also aids in reducing joint tenderness and swelling.

How Is Xeljanz Used?

Xeljanz is taken by mouth twice daily as a pill. Xeljanz XR is an extended release formula of the same treatment and is taken by mouth once daily as a pill.

What Are the Risks?

Xeljanz/Xeljanz XR may raise your risk for:

  • High lipid levels
  • High liver enzymes
  • Low blood count
  • Lymphoma and other malignancies
  • Gastrointestinal perforations

Common Side Effects

In clinical trials, the most common side effects were headaches, diarrhea, and upper respiratory infections.

Xeljanz Fact Sheet

Learn about Xeljanz for psoriatic arthritis.

Get your fact sheet
A woman doctor hands a prescription to a patient across a desk.

Systemic Treatments

Learn more about types of oral systemic, biologic, and biosimilar treatments including their risks and side effects.

Request your resource
Illustrated graphic of people around a rocket ship and computer.

Articles and Updates

Weekly updates on living your best life with psoriatic disease.

Subscribe

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Last updated on 3/25/25 by the National Psoriasis Foundation.

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2025 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.